7 completed, 1 active not recruiting. 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Active not recruiting 1 |
Follow 5-alpha Reductase Inhibitors: new trials by email Literature Review of 5-alpha Reductase Inhibitors trials Research Report on 5-alpha Reductase Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ultrasound IPP to Predict Response to Medical Therapy in LUTS/BPH Transabdominal ultrasound measurement of intravesical prostatic protrusion, Alpha-adrenergic blocker, 5-alpha reductase inhibitor - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Completed | Ain Shams University | 130 | 2025-12-30 | 2026-09-30 | |
| REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men REZŪM, alpha blocker and 5-alpha reductase inhibitor - Benign Prostatic Hyperplasia (BPH) | Not applicable | Active not recruiting | Boston Scientific Corporation | 155 | 2021-09-15 | 2026-10-13 |
| WEUSKOP5723: Prostate Cancer Study 5-alpha reductase inhibitors, Alpha-blockers - Prostatic Hyperplasia | Completed | GlaxoSmithKline | 1 | 2012-11-01 | 2016-11-09 | |
| Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies 5-Alpha Reductase Inhibitors - Atherosclerotic Cardiovascular Disease (ASCVD), Benign Prostatic Hypertrophy (BPH) | Completed | Chinese PLA General Hospital | 10000 | 2012-01-01 | 2025-09-29 | |
| Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database 5-alpha Reductase Inhibitor (5ARI) - Prostatic Hyperplasia | Completed | GlaxoSmithKline | 54459 | 2010-06-01 | 2012-08-27 | |
| Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia Adherent with 5-alpha-reductase inhibitor (5ARI) therapy, Non-adherent to 5ARI therapy - Prostatic Hyperplasia | Completed | GlaxoSmithKline | 35032 | 2010-04-01 | 2017-05-30 | |
| Sex Steroids and the Serotonin Transporter Testolactone undecanoate, Lynestrenol, Cyproterone Acetate - Transsexualism | Phase 4 | Completed | Medical University of Vienna | 32 | 2010-02-01 | 2014-01-03 |
| Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia Tamsulosin, Tadalafil, 5-Alpha Reductase Inhibitor - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Completed | Beni-Suef University | 240 | 2026-07-20 |
Prostatic Hyperplasia (7) · Lower Urinary Tract Symptoms (3) · Atherosclerosis (1) · Ejaculatory Dysfunction (1) · Erectile Dysfunction (1) · Gender Dysphoria (1) · Transsexualism (1) · Urinary Bladder Neck Obstruction (1)
GlaxoSmithKline (3) · Ain Shams University (1) · Beni-Suef University (1) · Boston Scientific Corporation (1) · Chinese PLA General Hospital (1) · Medical University of Vienna (1)
Egypt (2) · Australia (1) · Austria (1) · France (1)
Evanguelos Xylinas, Ass. Prof. (1) · Omar S Taha, MBBCh (1) · Romain Mathieu, Professor (1) · Rupert Lanzenberger, MD A/Prof (1)